newsfilter
← Latest News
GlobeNewswire·

Braveheart Bio to Participate in Cantor Global Healthcare Conference

  • Braveheart Bio, Inc. (NASDAQ: BRVE) will participate in the Cantor Global Healthcare Conference held September 9-11, 2026, in New York, NY.
  • Management will present a fireside chat on Thursday, September 10, 2026, at 3:20 p.m. EDT.
  • A live webcast of the event will be available on the company's investor relations website, with replays accessible in a temporary archive afterward.
  • The company is developing BHB-1893, a next-generation oral cardiac myosin inhibitor intended for obstructive & non-obstructive hypertrophic cardiomyopathy.
  • BHB-1893 is designed to address limitations of current therapies through rapid onset, consistent response depth, preserved systolic function, prompt reversibility, & simplified titration.